Ketamine for Treatment-Resistant Depression
Mustansiriya Medical Journal July 1, 2021 DOI: 10.4103/mj.mj_15_21 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression and major depressive disorder |
| Intervention | Ketamine |
| Topics | Depression Esketamine Ketamine |
| Key findings | Ketamine shows promise as a fast-acting antidepressant for treatment-resistant depression and may also be effective for posttraumatic stress disorder and acute suicidal ideation. |
Abstract
Major depressive disorder (MDD) is of influence on about 350 million individuals worldwide, which is causing disability consecution and damaging consequences to the affected community and individuals. Treatments as antidepressant are affecting the system of monoamine where symptoms of depressive were relived in about 50% of cases. Such ratio turns into obviously low in depressed persons who failed already to cure following 2 or additional antidepressant drugs at sufficient duration and doses regarding it a treatment-resistant depression (TRD). There is an obvious requisite for quick action and influenced treatments. Ketamine (KMN) is considered an anesthetic old drug that has a promising quick action as an antidepressant in TRD patients with MDD, concentrating on clinical issues, i.e. administration route, dose, and action duration. Other indication proposes that KMN might be influenced in stress disorder as posttraumatic and ideation as acute suicidal.